PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
Status:
Completed
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase
3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric
subjects between 6 to 12 years of age.